Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotech company Immutep (IMM) enrols its last patient in its trial on non-small cell lung cancer patients
  • 154 patients are participating in the study across 19 clinical sites in Australia, Europe, the UK and US
  • The trial will evaluate the combination of Immutep’s lead drug candidate, Efti with Merck & Co’s (MSD) KEYTRUDA in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer
  • Immutep says it expects to report further data from the trial at a scientific conference by early 2022
  • Immutep shares are up 6.60 per cent, trading at 56.5 cents at 3:43 pm AEST

Biotech company Immutep (IMM) has enrolled its last patient in its current lung cancer trial.

Recruitment is now complete for Stage 2 of Part B of Immutep’s Phase II TACTI-002 study on second line refractory non-small cell lung cancer patients.

A total of 154 patients are now participating in the trial across 19 clinical sites in Australia, Europe, the UK and US, with recruitment continuing for the expansion stage of Part A.  

The study is evaluating the combination of Immutep’s lead drug candidate, efti, with Merck & Co’s (MSD) KEYTRUDA in patients with second line head and neck squamous cell carcinoma, or non-small cell lung cancer in first and second line.

Immutep says data previously presented at the Society for Immunotherapy of Cancer 35th Anniversary 2020 Annual Meeting as part of a late breaker poster looked encouraging, especially when compared to alternative treatment options.

Immutep says it expects to report further data from the trial at a scientific conference by early 2022.

Immutep shares are up 6.60 per cent, trading at 56.5 cents at 3:43 pm AEST.

IMM by the numbers
More From The Market Herald
Artrya (ASX:AYA) - MD John Barrington (left) and Executive Director John Konstantopoulos (right)

" Cardiac imaging software company Artrya (ASX:AYA) up on public debut

Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering
Palla Pharma (ASX:PAL) -

" Palla Pharma (ASX:PAL) enters sale and leaseback of Coolaroo site

Palla Pharma (PAL) has entered into a sale and leaseback agreement of its $33.1 million manufacturing site in Melbourne.
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima (ASX:HXL) completes $1m SPP

Biotechnology company Hexima (HXL) has successfully completed its share purchase plan (SPP) and raised $1 million.

" Paragon Care (ASX:PGC) enters partnership with Centuria Healthcare for a healthcare facility

Paragon Care (PGC) has entered into a partnership with Centuria Healthcare for the 15-year lease of a state-of-the-art healthcare facility in Melbourne.